ArticleExpert review of anti-infective therapy2010
Present and future therapeutic strategies for melioidosis and glanders.
Article in Expert review of anti-infective therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 110 citations in OpenAlex.
- Isolation, serological and molecular methods in screening ofVeterinary research forum : an international quarterly journal · 2024Article
- Tracking the footsteps of Burkholderia mallei: determination of the molecular differences and potential resistance genes.Turkish journal of medical sciences · 2024Article
- Patient Presenting with Abscess Unresponsive to Treatment and Progressive to Osteomyelitis: A Rare CauseSisli Etfal Hastanesi tip bulteni · 2024Article
- Glanders (IDCases · 2023Article
- Ophthalmic implications of biological threat agents according to the chemical, biological, radiological, nuclear, and explosives framework.Frontiers in medicine · 2023Review
- Influence of genomic variations on glanders serodiagnostic antigens using integrative genomic and transcriptomic approaches.Frontiers in veterinary science · 2023Article
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
- One Health surveillance approaches for melioidosis and glanders: The Malaysian perspective.Frontiers in veterinary science · 2022Review
- Efficacy of finafloxacin in a murine model of inhalational glanders.Frontiers in microbiology · 2022Article
- Natural-Product-Based Solutions for Tropical Infectious Diseases.Clinical microbiology reviews · 2021Review
- A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Hijacking of the Host's Immune Surveillance Radars byFrontiers in immunology · 2021Review
- BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis.Frontiers in immunology · 2021Article
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Multicomponent gold nano-glycoconjugate as a highly immunogenic and protective platform againstNPJ vaccines · 2020Article
- Clinical repercussions of Glanders (Burkholderia mallei infection) in a Brazilian child: a case report.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- A Machine Learning-Based Raman Spectroscopic Assay for the Identification ofMolecules (Basel, Switzerland) · 2019Article
- Evaluating the role of Burkholderia pseudomallei K96243 toxins BPSS0390, BPSS0395, and BPSS1584 in persistent infection.Cellular microbiology · 2019Article
- Emerging role of biologics for the treatment of melioidosis and glanders.Expert opinion on biological therapy · 2019Review
- An in situ high-throughput screen identifies inhibitors of intracellularProceedings of the National Academy of Sciences of the United States of America · 2019Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.